Absci Corporation (ABSI) vs Ocular Therapeutix, Inc. (OCUL)

Absci Corporation and Ocular Therapeutix, Inc. are both Biotechnology companies. Absci Corporation and Ocular Therapeutix, Inc. are of similar size ($1.3B and $1.3B). Ocular Therapeutix, Inc. grew revenue faster over the last twelve months: −9.68% against −47.2%. Ocular Therapeutix, Inc. has the higher net margin (−648.6% vs −8,451.3%) and the higher return on invested capital (0.00% vs −182.0%). Across the 18 metrics below, Absci Corporation leads on 9 and Ocular Therapeutix, Inc. on 9.

Valuation

Metric ABSI OCUL Biotechnology median
P/E n/m n/m 10.01
P/S 875.75 26.90 9.02
P/B 5.96 3.07 2.13
Price to free cash flow n/m n/m 24.99
EV/EBITDA n/m n/m 0.64
EV/Sales 759.00 17.83 9.01
Earnings yield (10.47%) (24.30%) (34.01%)
Free cash flow yield (8.62%) (19.70%) (24.62%)

Profitability

Metric ABSI OCUL Biotechnology median
Gross margin 100.00% 87.32% 70.18%
Operating margin (8,812.31%) (680.91%) 0.00%
Net margin (8,451.31%) (648.64%) 0.00%
Free cash flow margin (7,550.91%) (530.00%) 0.00%
Return on equity (58.59%) (93.48%) (50.72%)
Return on assets (51.87%) (64.30%) (45.56%)
Return on invested capital (181.96%) 0.00% 0.00%

Growth

Metric ABSI OCUL Biotechnology median
Revenue growth (TTM) (47.18%) (9.68%) 7.42%
EPS growth (last fiscal year) 10.64% (16.39%) 29.36%
Revenue growth, 5-year CAGR (10.14%) 24.45% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABSI OCUL Biotechnology median
Debt to equity 0.00 0.17 0.00
Current ratio 9.64 9.12 4.72
Net debt to EBITDA 1.32 2.51 1.01

Dividend

Metric ABSI OCUL Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric ABSI OCUL Biotechnology median
Market cap 1.31b 1.32b 157.22m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack